Newsmeme!
Discover News you didn't know existed
Small Interfering Rna (Sirna)
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Liquidia teams with Abbott
Published January 7, 2009, 11:49 pm, The News & Observer
Durham company has role in developing cancer treatment.
Liquidia Technologies to collaborate with Abbott on siRNA therapeutics
Published January 7, 2009, 3:37 pm, News-Medical-Net
Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more ...
Liquidia Technologies Announces Collaboration with Abbott to Develop siRNA Therapeutics
Published January 7, 2009, 4:00 am, Business Wire via Yahoo! Finance
RESEARCH TRIANGLE PARK, N.C.----Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT® nanoparticles for the delivery of siRNA-based therapeutics.
Tekmira Partner Alnylam Files First IND For An RNAi Therapeutic Utilizing SNALP
Published January 5, 2009, 11:48 pm, PharmaceuticalOnline
Tekmira Pharmaceuticals Corporation announced recently that one of the company's collaborators, Alnylam Pharmaceuticals Inc., has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) seeking approval to begin a human clinical trial for a product candidate utilizing Tekmira's SNALP delivery technology.
Ensysce Biosciences Inc. Appoints Dr. D. Lynn Kirkpatrick as President and CEO
Published January 5, 2009, 5:17 am, Centre Daily Times
Ensysce Biosciences Inc. announced today the appointment of Dr. Lynn Kirkpatrick as President and CEO. Dr. Kirkpatrick has an extensive background in targeted small molecule cancer drug development, and has brought three agents from bench to bedside. Co-founder of ProlX Pharmaceuticals, Dr. Kirkpatrick was CEO from 1999 until its acquisition by Biomira Inc. in 2006. From 2006 through 2008 she ...
Ensysce Biosciences Inc. Appoints Dr. D. Lynn Kirkpatrick as President and CEO
Published January 5, 2009, 5:00 am, Business Wire via Yahoo! Finance
HOUSTON----Ensysce Biosciences Inc. announced today the appointment of Dr. Lynn Kirkpatrick as President and CEO. Dr. Kirkpatrick has an extensive background in targeted small molecule cancer drug development, and has brought three agents from bench to bedside.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |